Evidence map›Paper›PMID 39003776›Full record

ArticleEpigenetics2024

A dual-gene panel of two fragments of methylated IRF4 and one of ZEB2 in plasma cell-free DNA for gastric cancer detection.

Chunxiao Bu, Zhilong Wang, Xianping Lv, Yanteng Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chunxiao BuDepartment of Magnetic Resonance Imaging,The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhilong WangHenan Academy of Medical Sciences, Zhengzhou, Henan, China.
Xianping LvDepartment of Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yanteng ZhaoDepartment of Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID 0000-0002-9725-5776

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection is crucial for increasing the survival rate of gastric cancer (GC). We aimed to identify a methylated cell-free DNA (cfDNA) marker panel for detecting GC. The differentially methylated CpGs (DMCs) were selected from datasets of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The selected DMCs were validated and further selected in tissue samples (40 gastric cancer and 36 healthy white blood cell samples) and in a quarter sample volume of plasma samples (37 gastric cancer, 12 benign gastric disease, and 43 healthy individuals). The marker combination selected was then evaluated in a normal sample volume of plasma samples (35 gastric cancer, 39 control diseases, and 40 healthy individuals) using real-time methylation-specific PCR (MSP). The analysis of the results compared methods based on 2

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsDNA MethylationInterferon Regulatory FactorsStomach NeoplasmsZinc Finger E-box Binding Homeobox 2AdultAgedFemaleHumansInterferon Regulatory Factor-4MaleMiddle AgedBiomarkers, TumorCell-Free Nucleic AcidsInterferon Regulatory Factor-4Interferon Regulatory FactorsZEB2 protein, humanZinc Finger E-box Binding Homeobox 2cfDNAGastric cancer detectionIRF4methylated DNA markerplasmareal-time methylated-specific PCRZEB2

Identifiers

PMID39003776
PMCPMC11249030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.